JS004 in combination with toripalimab

BIOLOGICAL2 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd.

Conditions

Advanced Lung CancerHodgkin Lymphoma

Phase 1

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

CompletedNCT05000684

Shanghai Junshi Bioscience Co., Ltd.Advanced Lung Cancer

Start: 2021-08-27End: 2024-10-31Updated: 2025-02-20

Phase 3

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

RecruitingNCT06170489

Shanghai Junshi Bioscience Co., Ltd.Hodgkin Lymphoma

Start: 2023-12-28End: 2027-09-30Target: 185Updated: 2025-02-28

Related Papers

Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC).

Journal of Clinical Oncology2023-06-018 citations